About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Find trials: by AGENT | by TYPE of LYMPHOMA AND treatment status | of INTEREST

   Search Site | Ask Question | Sign Guest book |  How to Help!

Patients Against Lymphoma

 

Locate Trials by type of agent 

In the News | Of special interest | Monoclonal antibody | Bispecific antibody
Antibody-drug conjugates | Radioimmunotherapy | Immune mediated | Cytotoxic
epigenetic agents | bcl-2 (apoptosis) | Kinase inhibitors | mTOR | Other

Also find trials by:
lymphoma type AND treatment status | Trials of Interest | Agents that target disease pathways

 

Last update: 03/02/2014


Agents of special interest -
with encouraging clinical reports of late:

bullet
Adcetris ®  (SGN-35 / brentuximab vedotin)  antibody-drug conjugate: anti-cd30 + antitubulin  Find trials
active in relapsed DLBCL
bullet
GA-101 (Obinutuzumab), next generation cd20 antibody  Find trials
bullet
Vidaza ® (epigenetic / 5-Azacytidine / ) Find trials 
pretreatment priming for DLBCL
bullet
Lenalidomide (immune modulation with Rituxan  Find trials
bullet
Immune checkpoint antibodies (PD1/L):  Find trials 
with Rituxan and as single agent
bullet
Targeting apoptosis (bcl-2 ABT199):  Find trials 
with Rituxan, single agent CLL 
bullet
Cd19 CAR T-cell therapy  Find trials 
chemotherapy-refractory CLL / Lymphoma
bullet
Ibrutinib (PCI-32765) Find trials
relapsed CLL, MCL, WM, and lymphoma, single agent or with Rituxan
bullet
Idelalisib / GS-1101 (formerly CAL101)  Find trials
relapsed CLL, MCL, WM, and lymphoma, single agent or with Rituxan


In the News

bullet
ASCO Post: “Novel Agents Show Activity in relapsed Non-Hodgkin Lymphoma”
including CRs http://bit.ly/1dSn1gv
Promising reports in this article - impressive outcomes - particularly for single agents in relapse setting.

SAR 245409 is a potent oral pan-inhibitor of PI3K

     * List Results - ClinicalTrials.gov http://1.usa.gov/1hyV6Wi

copanilisib (BAY 80-6946), is an intravenously administered compound that has significant activity against alpha and delta isoforms of PI3K; the delta isoform has a role in B-cell signaling, development

      * List results -  ClinicalTrials.gov http://1.usa.gov/1glACLs

PNT2258 DNAi molecule targets the noncoding, nontranscribed regulatory region of the Bcl2 gene.

       * List Results - ClinicalTrials.gov http://1.usa.gov/1nQQad1 
bullet
New by agent:  XmAb5574 / MOR00208 (optimized cd19 Mab)  Find trials

About study drug From morphosys.com: http://bit.ly/1kiAP8s
bullet
New by agent: Ruxolitinib  (inhibitor of cytokine-signaling) - Find trials 

Related Citations for PubMed (Select 22869151) - PubMed - NCBI

Background on this drug for other indications: wikipedia.org

 

 
Agent

BOLD names are
FDA approved agents


 
B or T cell 
 
Target
of Drug
 
Approved
Indication
 
Queries

Locate
Studies on
ClinicalTrials.gov
 

Counting
 Clicks
as of
3/7/13


4,651
Find
Clinical Reports
on Agent

Google
Scholar
 

Monoclonal antibodies (Mab)
  See also Immune mediated

Monoclonal antibodies (MAbs) are similar to antibodies produced by the body in response to infection.  MAbs bind to specific receptor expressed on the tumor and some normal cells.

 

Agent
Click to search for
 mechanism of action

  Target  

Find Trials


Count
 
Clinical Reports

MEDI-551 (humanized antibody) 

B cd19 - Find trials
>
 53 Reports
By request:  all cd-19-based agents B cd19   Find trials NEW  

 
Arzerra
® (Ofatumumab)

B cd20 CLL Find trials
>
183 Reports

Rituxan ® (Rituximab / Mabthera)

B cd20 NHL Find trials
>
70 Reports

GA-101 (Obinutuzumab)

B cd20 - Find trials
>
398 Reports

Ublituximab

B cd20 -  Find trials
>
18  

Veltuzumab / Immu-106 / Ha20

B cd20 - Find trials
>
11 Reports

Epratuzumab

B cd22 - Find trials
>
84 Reports

Lumiliximab

B cd23 - Find trials
>
40 Reports

SGN-30

B / T cd30 - Find trials
>
53 Reports

TRU-016

B cd37 - Find trials
>
72 Reports

Zanolimumab

T cd4 - Find trials
>
53 Reports

Campath ® (alemtuzumab)

B cd52 CLL Find trials
>
33 Reports

MDX-1411

B / T cd70 - Find trials
>
 
50 Reports

Milatuzumab / hLL1

B cd74 - Find trials
>
50 Reports

IMMU-114 (anti-HLA-DR)

  HLA-DR - Find trials
>
1 Reports

Mogamulizumab (Mogo)
(KW-0761; AMG-761)

T CCR4 - Find trials
>
45 Reports

PAL

Bispecific antibodies

Binding two receptors expressed on tumor cells and/or other immune cells

 

Agent

  Target  

Find Trials

Count Reports

DT2219ARL

anti-CD19/22 Bi
specific antibody + immunotoxin

B cd19 cd22 Initial
count:
72 >
 Find trials
 >
 

85

 

Reports

Blinatumomab / MT103 / BiTe)

B cd3 cd19 - Find trials
>
 
94 Reports

antibody-drug conjugates

Uses antibodies to delivers toxins to cells that have a specific target receptor

Agent

  Target  

Find Trials

Count Reports

SGN-CD19A
anti-CD19 + toxin

B cd19 NEW Find trials
>
 
3 Reports

SAR3419
anti-CD19 + maytansinoi

B cd19 - Find trials
>
 
104 Reports

DT2219ARL
anti-CD19 & 22 antibody + immunotoxin

B cd19 cd22 - Find trials
>
 
100 Reports

Inotuzumab Ozogamicin
anti-CD22 + calicheamicin

 

B cd22 - Find trials
>
 
206 Reports

DCDT2980S
anti-CD22, conjugated to MMAE

B cd22 - Find trials
>
 
18 Reports

LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin

B cd25 - Find trials
>
 
28 Reports

Adcetris ® 
(SGN-35 / brentuximab vedotin)
anti-cd30 + antitubulin

B/T cd30 HL / ALCL Find trials
>
178 Reports

Technical - PK / dosing

Radio-immunotherapy

Uses antibodies to delivers radiation to cells in a targeted way

Agent

  Target  

Find Trials

Count Reports

Betalutin

B cd37 NHL Find trials
>
NEW Reports

Bexxar ®
anti-CD20 + iodine 131
(Tositumomab, Iodine I 131)

B cd20 NHL Find trials
>
 
63 Reports

Zevalin ®
anti-CD20 + Yttrium 90

(Ibritumomab tiuxetan)

B cd20 NHL Find trials
>
 
79 Reports

epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90 

B cd22 - Find trials
>
 
63 Reports

Immune-mediated

Immune mediated therapy assists in helping the immune system to attack the tumor.

See also antibody agents, and radioimmunotherapy, which may also be immune-mediated

Agent

  Target  

Find Trials

Count Reports

Anti-PD-1 antibody

pidilizumab (CT-011)

OR

BMS-936558 (
nivolumab)
 
 
(Immune checkpoint blockade)

B PD-1 (P7) Initial
count: 195


 
>
Find trials

>
Total
272
Reports

ipilimumab

anti-CTL-A (MXD-010)

(Immune checkpoint blockade)

B CTL-A
t-reg
-

Find trials
>
 

15 Reports

immunocytokine therapy

composed of two immune components – antibodies and cytokines

- - - Find trials
>
 
6 Reports


Revlimid ® / Lenalidomide / CC 5013

(Immune modulating / cereblon)

- unknown MDS / myeloma Find trials
>
 
95 Reports

Lenalidomide AND Rituxan

- unknown + cd20 New combination Find trials
 >
 
4 Reports

Pomalidomide 

(Immune modulating)

- unknown NEW Find trials
>
 
5 Reports

T-cell therapy

(adoptive immunotherapy)

B or T - - Find trials
 >
 
14  

cd19 CAR T-cell therapy

(CAR - chimeric antigen receptor)

(
adoptive immunotherapy)

B cd19 Initial count: 148 >  (updated)

> (New count)
Find trials 

(revised query 10/11)

 



184
 
Reports

About by PAL

Vaccine (idiotype) therapy

B tumor antigen - Find trials
 >
32 Reports

Cytotoxic Agents

Damage the DNA of rapidly dividing cells, triggering apoptosis (programmed cell death)

 

Agent

  Target  

Find Trials

Count Reports


Treanda ®

(Bendamustine)
 
 

B or T DNA NHL/CLL Find trials
>
78 Reports


Bendamustine
phase 3 trials

B or T DNA NHL/CLL Phase 3 trials
>
25 Reports


Folotyn ® (Pralatrexate)

- DNA T-cell Find trials
>
6 Reports


Pixantrone
 

Request:  Open Studies >
  

B DNA - Find trials

>
 
7

Reports

Targeted Agents

    

Epigenetic Agents

Agents that modify gene expression (by methylation or acetylation of histones and other elements) can reprogram how tumor cells behave: grow, die, or differentiate.

DNA hypo/hyper-methylation

can reactivate tumor suppressor genes by altering methylation

Hypermethylation-associated silencing of tumor suppressor genes has been shown to occur in lymphoid/hematopoietic malignancies, disrupting many cellular pathways.1-3 Unlike genetic alterations in cancer, hypermethylation changes are potentially reversible by pharmacologic inhibition of DNA methylation.4 The cytidine analogs 5-aza-2′-deoxycytidine and 5-azacytidine are capable of reactivating tumor suppressor genes that were silenced by hypermethylation.4

Agent

  Target  

Find Trials

Count Reports


Vidaza ®
 
(5-Azacytidine)

B DNA hypo-methylation initial
count: 19
>

 Find trials
>
20 Reports

HDAC inhibition

interferes with the function of histone deacetylase - modifying gene expression    About by PAL

 

Agent

  Target  

Find Trials

Count Reports


Abexinostat (PCI-24781)

  HDAC   Find trials
>
25 Reports

Belinostat (PXD101)
T or B HDAC   Find trials
>
32 Reports

Panobinostat (LBH589)
T or B HDAC   Find trials
>
54 Reports

Romidepsin ® (Depsipeptide)
T or B HDAC Approved for T-cell lymphoma Find trials
> 
21 Reports

Valproic acid
T or B HDAC AML / MDS Find trials
 >
78 Reports
Zolinza ® (Vorinostat)
T or B HDAC Approved for T-cell lymphoma Find trials
>
87 Reports

BCL-2 inhibitors
(apoptosis inhibitor)

Binds to BCL-2 pathway involved in the blocking of apoptosis (programmed cell death)

 

Agent

  Target  

Find Trials

Count Reports

ABT-199 

B bcl-2
pathway
 

Find trials
>

54 Reports

ASCO report

Obatoclax mesylate / GX15-070)
B bcl-2
pathway
- Find trials
>
51 Reports

mTOR

Binds the mTOR pathway that promotes survival and cell growth

 

Agent

  Target  

Find Trials

Count Reports

CC-223

dual mTOR inhibitor (oral)
B mTOR - Find trials
>
21 Reports

Everolimus / RAD001 (oral)
B mTOR - Find trials
>
52 Reports

Leukemia - A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma


Temsirolimus / CCI-779 (IV)
B mTOR - Find trials
>
38 Reports

Kinase inhibitors

Inhibit transcription pathways that are overactive in cancer

 

B-cell Receptor Pathway
 
Target
       

AVL-292
B Bruton's tyrosine (Btk) - Find trials
>
70 Reports
 
Idelalisib / GS-1101 HOT

(formerly CAL101)
B PI3k delta CLL and NHL Find trials
>
488 Reports

* Lymphomahub 2013: PI3K inhibitors
 


Ibrutinib
(PCI-32765)  HOT
 
B Bruton's tyrosine (Btk) FDA breakthrough designation Find trials
>
544 Reports

About by PAL


Ibrutinib for
CLL -Open Studies Only

B - - Find trials
>
NEW -
Other
 
Target
 
Find Trials
Count
Reports


AEB071 (Sotrastaurin)

subtype
of DLBCL
 Protein Kinase C Inhibitor   Find trials
>
NEW

Report


Alisertib (MLN8237)

* Helio 2013: Alisertib active in relapsed, refractory B-cell, T-cell non-Hodgkin’s lymphomas  http://bit.ly/18sChgG
T Aurora Kinase A t-cell
lymphoma
Find trials
>
23 Reports

IPI-145

B or T (PI3K)-delta and PI3K-gamma   Find trials
>
NEW Reports

Other agents

 
 Lymphoma / CLL trials of new agents with search of literature for underlined agent
* Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma - Full Text View - ClinicalTrials.gov http://1.usa.gov/19YXLEf 

* AZD6738 First Time in Patient Multiple Ascending Dose Study - Full Text View - ClinicalTrials.gov http://1.usa.gov/19TnU1m

* A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma - Full Text View - ClinicalTrials.gov http://1.usa.gov/15MC83D

* A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma - Full Text View - ClinicalTrials.gov  http://1.usa.gov/1d6jTxS

* A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab - Full Text View - ClinicalTrials.gov http://1.usa.gov/1b6LCby

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies http://bit.ly/1aXT0cB 

Andy: "PF-05082566 is an anti-CD-137 agonist antibody that is designed to help the immune system go after the lymphoma cells with Rituxan attached to them."



 


Agent

  Target  

Find Trials

Count Reports
PD 0332991
  Cdk - Find trials
>
19 Reports

ISIS 481464 (AZD9150)

antisense oligonucleotide
inhibitor of STAT3

  STAT3   Find trial
>
NEW Report
YM155
B survivin kinase - Find trials
>
61 Reports
proteasome inhibitors

MLN970 / Bortezomib /
Velcade
® , Carfilzomib,
CEP 18770 
  proteasome inhibitors - Find trials
>
10 Reports
TL32711  
  inhibitors of apoptosis   Find trials
 >
8 Reports

Discontinued agents

 
 
Enzastaurin
B C-beta - Find trials
>
25 Reports
Navitoclax / ABT-263 >
 
Discontinued due to improvement in safety with ABT-199 above
B bcl-2
pathway
- http://bit.ly/5fcv13 99 Reports
             

See also Find Clinical Trials based on Type of Lymphoma and Clinical Circumstance

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.